Evidence map›Paper›PMID 36719496›Full record

ArticleEuropean radiology2023

Prognostic value of CT-derived coronary artery disease characteristics varies by ASCVD risk: insights from the PROMISE trial.

Borek Foldyna, Thomas Mayrhofer, Michael T Lu, Júlia Karády, Márton Kolossváry, Maros Ferencik, Svati H Shah, Neha J Pagidipati, Pamela S Douglas, Udo Hoffmann

Open access · greenAbstract read
In one paragraph

Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Whys and Wherefores of Coronary Arterial Positive Remodeling.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Borek FoldynaCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 400, Boston, MA, 02114, USA. bfoldyna@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-2466-4827
Thomas MayrhoferCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 400, Boston, MA, 02114, USA.
Michael T LuCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 400, Boston, MA, 02114, USA.
Júlia KarádyCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 400, Boston, MA, 02114, USA.
Márton KolossváryCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 400, Boston, MA, 02114, USA.
Maros FerencikKnight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Svati H ShahDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Neha J PagidipatiDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Pamela S DouglasDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Udo HoffmannInnovative Imaging Consulting LLC, 163 Longfellow Rd, Waltham, MA, 02453, USA. udo@innovativeimagingconsulting.com.
Harvard University · USDuke University · USAstraZeneca (United States) · USOregon Health & Science University · USSemmelweis University · HU

Funding

PROMISE Trial: Clinical Coordinating CenterR01HL098237 · NHLBI · DUKE UNIVERSITY · PI DOUGLAS, PAMELA SUSAN · 2009 to 2014
$27.3M
PROMISE Trial: SDCCR01HL098236 · NHLBI · DUKE UNIVERSITY · PI LEE, KERRY L · 2009 to 2014
$5.0M
Clinical and Molecular Epidemiology of High Risk Coronary PlaqueR01HL146145 · NHLBI · DUKE UNIVERSITY · PI DOUGLAS, PAMELA SUSAN, FOLDYNA, BOREK · 2019 to 2022
$4.8M
PROMISE Trial: Dx CoreR01HL098305 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HOFFMANN, UDO · 2009 to 2014
$3.5M
PROMISE Trial: EQOL Coordinating CenterR01HL098235 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2009 to 2014
$1.6M
NHLBI NIH HHS R01 HL098235NHLBI NIH HHS R01HL098235NHLBI NIH HHS R01 HL098236NHLBI NIH HHS R01HL098236NHLBI NIH HHS R01 HL098237NHLBI NIH HHS R01HL098237NHLBI NIH HHS R01 HL098305NHLBI NIH HHS R01HL098305NHLBI NIH HHS R01 HL146145NHLBI NIH HHS R01HL146145
6 · The paper itself

Abstract

objectivesTo compare the prognostic value of individual CT-derived coronary artery disease (CAD) characteristics across categories of clinical cardiovascular risk.

methodsThe central core laboratory assessed coronary artery calcium (CAC), obstructive CAD (stenosis ≥ 50%), and high-risk plaque (HRP) in stable outpatients with suspected CAD enrolled in the PROMISE trial. Multivariable Cox regression models (endpoint: unstable angina, nonfatal myocardial infarction, or all-cause mortality; median follow-up: 2 years) were used to compare hazard ratios (HR) of the CT measures between low-borderline (< 7.5%) and moderate-high (≥ 7.5%) atherosclerotic cardiovascular disease (ASCVD) risk based on the pooled cohort equation.

resultsAmong 4356 included patients (aged 61 ± 8 years, 52% women), 67% had ASCVD risk ≥ 7.5%. Stratified by ASCVD risk, CAD ≥ 50% had nearly threefold greater HR in individuals with ASCVD < 7.5% (aHR, 6.85; 95% CI, 2.33-20.15; p < 0.001) vs. ASCVD ≥ 7.5% (aHR: 2.66, 95% CI: 1.67-4.25, p < 0.001; interaction p = 0.041). CAC predicted events solely in ASCVD ≥ 7.5% patients (aHR: 1.92, 95% CI: 1.01-3.63, p = 0.045; interaction p = 0.571), while HRP predicted events only in ASCVD < 7.5% (aHR: 3.11, 95% CI: 1.09-8.85, p = 0.034; interaction p = 0.034).

conclusionsPrognostic values of CT-derived CAD characteristics differ by ASCVD risk categories. While CAD ≥ 50% has the highest prognostic value regardless of ASCVD risk, CAC is prognostic in high and HRP in low ASCVD risk. These findings suggest that CAD ≥ 50% and HRP detection rather than CAC scoring may better risk-stratify symptomatic low-risk patients and thus potentially improve downstream care. KEY POINTS: • Prognostic value of individual CT-derived CAD characteristics differs by categories of cardiovascular risk. • Presence of obstructive coronary artery stenosis ≥ 50% has the highest prognostic value regardless of cardiovascular risk. • Coronary artery calcium is independently prognostic in high and high-risk plaque features in low cardiovascular risk.

Indexed as

AtherosclerosisCoronary Artery DiseasePlaque, AtheroscleroticCalciumCoronary AngiographyFemaleHumansMalePredictive Value of TestsPrognosisRisk AssessmentRisk FactorsTomography, X-Ray ComputedCalciumComputed tomography angiographyCoronary artery diseaseCoronary stenosisHeart disease risk factorsPrognosis

Identifiers

PMID36719496
PMCPMC10765563
OpenAlexW4318618398

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.